Vergelijking

Semaglutid vs. VK2735

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

910463-68-2

geen gegevens

Molecuulmassa

4113.6 g/mol

geen gegevens

Halfwaardetijd

165 h

geen gegevens

Sequentie

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

geen gegevens

Werkingsmechanisme

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Semaglutid	VK2735
Zwitserland	Op recept	—
Duitsland	Op recept	Niet goedgekeurd
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Semaglutid

Volledige vermelding →

VK2735

Volledige vermelding →

Frequently asked questions

What is the difference between Semaglutid and VK2735?: Semaglutid is classified as "Metabool", while VK2735 is classified as "Metabool". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Semaglutid or VK2735?: The highest available evidence level is "Humane RCT" for Semaglutid and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Semaglutid and VK2735 in Germany and the United States?: Duitsland: Semaglutid — Op recept, VK2735 — Niet goedgekeurd. Verenigde Staten: Semaglutid — Op recept, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Semaglutid

VK2735

Zwitserland

Op recept

—

Duitsland

Op recept

Niet goedgekeurd

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Semaglutid and VK2735?

Semaglutid is classified as "Metabool", while VK2735 is classified as "Metabool". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Semaglutid or VK2735?

The highest available evidence level is "Humane RCT" for Semaglutid and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Semaglutid and VK2735 in Germany and the United States?

Duitsland: Semaglutid — Op recept, VK2735 — Niet goedgekeurd. Verenigde Staten: Semaglutid — Op recept, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.